crossover design when use ABEL with two test products [Design Issues]

posted by BEQool  – 2024-02-22 10:15 (845 d 09:16 ago) – Posting: # 23870
Views: 6,513

Hello,
so the most appropriate design for 2 test treatments and replicated reference is a below one?

T1  R   T2   R

R   T1  R   T2

T2  R   T1  R

R   T2  R   T1


Do you think EMA regulators would have any objections if this is was pivotal study (of course bearing Bonferroni adjustment in mind)?

Probably following designs would be worse?:

a) EMA suggested replicate design with additional test treatment
TRR|T2
RTR|T2
RRT|T2


b) 3x6x3 Williams design with additional reference treatment
ABC|C
ACB|C
BAC|C
BCA|C
CAB|C
CBA|C


Best regards
BEQool

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
113 visitors (0 registered, 113 guests [including 13 identified bots]).
Forum time: 20:31 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5